---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-014663"
form_type: "8-K"
ticker: "PAHC"
cik: "0001069899"
company_name: "PHIBRO ANIMAL HEALTH CORP"
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:17:57.404101+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Phibro Q1 net sales $260.4M (+13% YoY), net income $7.0M vs loss; updates FY25 guidance

## Summary
- Net sales $260.4M (+13% YoY); net income $7.0M vs net loss $8.0M; diluted EPS $0.17 vs -$0.20.
- Adjusted EBITDA $30.7M, +64% YoY; adjusted diluted EPS $0.35 vs $0.14 prior year.
- Updated FY2025 guidance: net sales $1.05B-$1.10B; Adjusted EBITDA $124M-$132M (15% growth).
- Discontinued atopic dermatitis project; expects ~$200M sales from Zoetis MFA portfolio in FY2025.
- Gross margin improved 280 bps to 32.1%; interest expense up $3.1M due to refinancing.

## SEC filing metadata
- accession: 0001558370-24-014663
- form_type: 8-K
- ticker: PAHC
- cik: 0001069899
- company_name: PHIBRO ANIMAL HEALTH CORP
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069899/000155837024014663/0001558370-24-014663-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069899/000155837024014663/pahc-20241105x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-014663
- JSON: https://secwatch.observer/filing/0001558370-24-014663.json
- Plain text: https://secwatch.observer/filing/0001558370-24-014663.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.